Study Links Oxalate in Plant-Based Foods to Inflammatory Bowel Disease Risk
A study led by researchers from the University of North Carolina has found a potential link between oxalate, a compound present in various healthy plant-based foods, and inflammatory bowel disease (IBD). Foods such as spinach, beetroot, rhubarb, almonds, and sweet potatoes, known for their health benefits, may pose risks for certain individuals due to oxalate. While oxalate is typically excreted from the body without harm, this research indicates that some individuals may struggle to process it effectively, leading to gut issues.
Published in the journal Cellular and Molecular Gastroenterology and Hepatology, the study involved measuring dietary oxalate levels against stool samples from 46 participants, including those diagnosed with Crohn's disease, one of the two main types of IBD. Gastrointestinal biologist Anna Salvador noted that both IBD patients and healthy individuals consumed similar amounts of plant-based foods, yet those with Crohn's disease exhibited higher levels of oxalate in their stools. This finding suggests that the issue may not solely stem from dietary intake but rather from how the gut processes oxalate.
The researchers also examined the activity of transporter proteins, specifically SLC26A2 and SLC26A3, which are responsible for absorbing oxalate in the gut. Analysis of tissue samples from individuals with Crohn's disease, ulcerative colitis (the other primary IBD subtype), and healthy controls revealed that the genes producing these proteins were less active in the IBD samples.
In addition to human studies, the researchers conducted experiments on mice with induced intestinal inflammation. The results indicated that mice fed additional oxalate experienced more severe weight loss, prolonged intestinal inflammation, and lower survival rates. Laboratory tests showed that oxalate heightened the inflammatory response of mouse immune cells, indicating that the relationship between oxalate and IBD may involve immune system reactions rather than direct damage.
The findings of this study highlight dietary oxalate as a potentially modifiable factor in managing intestinal inflammation. The researchers emphasize the importance of considering individual variations in dietary exposure and oxalate metabolism in the context of IBD. Future research may focus on targeting the transporter proteins to enhance oxalate clearance from the gut, potentially reducing its harmful effects.
Moreover, the study examined another oxalate transporter, SLC26A6, finding that a less active gene variant was associated with more severe cases of Crohn's disease in a sample of 131 patients. Geneticist Shehzad Sheikh remarked that this research opens new therapeutic avenues connecting diet to gut inflammation for those living with Crohn's disease or ulcerative colitis.
While the study underscores the role of diet in IBD, the researchers do not advocate for the elimination of oxalate-rich foods from diets. Instead, they suggest that moderating oxalate intake may be beneficial for some individuals. Future studies with larger participant groups will further explore the mechanisms involved and identify those who may be particularly sensitive to oxalate.




